Home Pre-Screening Sleep Apnea Device Now Supports Multiple Languages NEW YORK, June 30
NEW YORK, June 30 /PRNewswire-FirstCall/ -- SPO Medical Inc. (SPOM), a
leading developer of biosensor and microprocessor technologies for use in
portable monitoring devices, today announced that it has released its PulseOx
7500(TM) supporting GUI (graphic user interface) and report generation in
multiple languages including French, Italian, German and Spanish ("FIGS")
along with English. The Company believes by supporting FIGS languages it will
be able to address the growing interest in the PulseOx 7500(TM) across
European markets and the Spanish speaking markets of the Americas.
Millions of people suffer from sleep apnea worldwide. Sleep apnea is a
sleep disorder characterized by pauses in breathing during sleep. Each
episode, called apneas, lasts long enough so that one or more breaths are
missed, and occurs repeatedly throughout sleep disturbing a person's sleep
pattern. Symptoms may be present for years, even decades without
identification, during which time the sufferer may become conditioned to the
daytime sleepiness and fatigue associated with significant levels of sleep
disturbance. Such fatigue is known to be the cause of road accidents,
industrial accidents and reduction in performance at the work place.
Typically, people with sleep disorder symptoms are referred by their
primary care physician to third-party sleep clinics for overnight monitoring
at the clinic facility, and depending on the diagnosis, are prescribed an
appropriate medical remedy. The PulseOx 7500(TM) designed for maximum comfort
and flexibility, enables doctors and other medical professionals to monitor
patients from the convenience of the patient's home. Data is collected and
stored overnight by wearing the PulseOx 7500(TM) wrist-watch configuration
while the user sleeps; the next morning, the data is easily downloaded by the
family care or general practitioner for analysis using supplied reporting
software.
"We are delivering this new product feature as a direct result of
increased demand from our European sales distributors. Those caring for sleep
apnea sufferers recognize the value proposition of the PulseOx 7500(TM) and
our cost-effective product is now available to a wider multi-language
community as an effective pre-screening device for detecting sleep disorders
in the comfort of a patient's home," commented Michael Braunold, President
and CEO of SPO Medical. Mr. Braunold continued, "Introducing the additional
languages once again demonstrates our commitment to extend our technological
applications to meet the diverse needs of our worldwide customer base."
To date SPO Medical has introduced several other devices currently
selling in close to 40 countries worldwide that use the Company's proprietary
Reflective Pulse Oximetry (RPO) technology for accurate and reliable
measurements of blood oxygen saturation (SpO2) and heart rate; they include
the PulseOx 5500(TM) - a stand-alone homecare spot check monitor; Check
Mate(TM) - a device for the sports and aviation markets that demand measuring
SpO2 and heart rate during high-altitude activities; PulseOx 6000(TM), a
professional stand-alone spot check monitor and the PulseOx 6100(TM) which is
a professional hand-held monitor. Most recently the Company announced its
entry in to the homecare baby monitoring market with its first product due in
2009.
About SPO Medical:
SPO Medical (SPOM) a leading developer of biosensor and microprocessor
technologies for use in portable monitoring devices to capture life-saving
and life-enhancing information within four key markets: medical care; home
and remote-care; sports and wellness; and safety and security. Its patented
technology uses information gathered from the reflectance of light on the
human blood stream, in a non-invasive manner, to monitor key vital signs. The
Company distributes its products through a network of distributors and also
licenses its technologies to appropriate client corporations for
commercialization and distribution. For more information, visit
http://www.spomedical.com and http://www.spobaby.com
Forward Looking Statements:
This press release contains forward-looking statements that involve
substantial uncertainties and risks. These forward-looking statements are
based upon our current expectations, estimates and projections about our
business and our industry, and that reflect our beliefs and assumptions based
upon information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on our current
expectations about future events. These forward-looking statements are not
guarantees of future performance and are subject to risks, uncertainties and
assumptions that are difficult to predict. Our actual results, performance or
achievements could differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors, including but
not limited to, market acceptance of our new products, changes in economic
conditions generally and the medical devices market specifically, changes in
technology, legislative or regulatory changes that affect us, the
availability of working capital, the introduction of competing products,
changes in our operating strategy or development plans and the risks and
uncertainties discussed under the heading "Risk Factors" in Item 1 of our
Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We
undertake no obligation to revise or update any forward-looking statement for
any reason.
Investor Contacts:
SPO Medical Contact:
Michael Braunold, President and CEO
+1-866-991-SPOM (7766)
investors@spomedical.com
Investor Relations Contact:
Howard Gostfrand / David Sasso
+1-305-918-7000
info@amcapventures.com
SOURCE SPO Medical Inc.
